Using miRNA-101 as a Blood Test for Diagnosing Liver Cancer in Egyptian Patients
Author Information
Author(s): Sharafeldin Mostafa A., Suef Reda A., Mousa Adel A., Ziada Dina H., Farag Mohamed M. S.
Primary Institution: Al-Azhar University
Hypothesis
The study aims to investigate the miRNA-101 differential expression in Egyptian HCV-induced HCC patients’ serum versus HCV liver cirrhosis as prospective diagnostic biomarkers compared to alpha-fetoprotein.
Conclusion
miR-101 is a promising non-invasive biomarker for the early detection of HCV-associated hepatocellular carcinoma, showing higher sensitivity and specificity than alpha-fetoprotein.
Supporting Evidence
- miR-101 levels were significantly higher in HCC patients compared to cirrhosis and control groups.
- miR-101 showed a sensitivity of 92.5% and specificity of 97.5% for diagnosing HCC.
- Elevated miR-101 levels correlated with larger tumor sizes and advanced disease stages.
Takeaway
Doctors can use a blood test for miR-101 to help find liver cancer in patients with hepatitis C, which is better than the usual test.
Methodology
The study involved a retrospective case-control design with blood samples collected from 100 subjects, including HCV-induced HCC patients, cirrhosis patients, and healthy controls, followed by RT-qPCR analysis of miR-101 levels.
Potential Biases
Potential biases may arise from the retrospective nature of the study and selection criteria for participants.
Limitations
The study's cross-sectional design limits the ability to evaluate the prognostic value of miR-101 over time.
Participant Demographics
The study included 40 HCV-induced HCC patients (23 males, 17 females), 40 cirrhosis patients (26 males, 14 females), and 20 healthy controls (11 males, 9 females).
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI: 0.909 — 1.002
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website